Open Access

Effects of diabetes on the rebleeding rate following endoscopic treatment in patients with liver cirrhosis

  • Authors:
    • Xi Wang
    • Xuecan Mei
    • Derun Kong
  • View Affiliations

  • Published online on: June 11, 2020     https://doi.org/10.3892/etm.2020.8876
  • Pages: 1299-1306
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In the present study, the effects of diabetes on rebleeding following endoscopic treatment were assessed in patients with liver cirrhosis. A retrospective analysis of patients who underwent endoscopic variceal ligation (EVL) or endoscopic injection sclerotherapy (EIS) at the First Affiliated Hospital of Anhui Medical University (Hefei, China) between June 2015 and March 2018 was performed. The patients were divided into the EVL and the EIS groups and each group was subdivided into diabetic and non‑diabetic groups. The post‑operative rebleeding rate was compared between the EVL and the EIS groups and between the diabetic and non‑diabetic patients. The differences in the post‑operative rebleeding rate of diabetic patients with hepatogenic and non‑hepatogenic diabetes and in patients with different liver function grades were also determined. In the total patient cohort, the rebleeding rate in the EVL subgroup (11.3, 16.5 and 23.5%) was not significantly different compared with that in the EIS subgroup (9.8, 17.4 and 29.3%) at 1, 3 and 6 months following surgery, respectively (P=0.724, 0.868 and 0.339). In the total diabetic group, the rebleeding rate in the EVL subgroup (25.0, 36.1 and 44.4%) was not significantly different compared with that in the EIS subgroup (20.6, 32.4 and 47.1%) at 1, 3 and 6 months following surgery (P=0.660, 0.741 and 0.826, respectively). In the EVL group, the rebleeding rate in the diabetic subgroup (25.0, 36.1 and 44.4%) was higher than that in the non‑diabetic subgroup (5.1, 7.6 and 13.9%) at 1, 3, and 6 months following surgery and the differences were significant (P=0.005, <0.001 and <0.001, respectively). In the EIS group, the rebleeding rate in the diabetic subgroup (20.6, 32.4 and 47.1%) was significantly higher than that in the non‑diabetic subgroup (3.4, 8.6 and 19.0%) at 1, 3 and 6 months following surgery (P=0.021, 0.004 and 0.004, respectively). Adjustment for age and liver function grade in the EVL and EIS groups was performed using binary logistic regression and the parameter diabetes was indicated to be a risk factor for post‑operative rebleeding (P<0.05). No significant difference was noted in the rate of rebleeding between patients with hepatogenic diabetes and non‑hepatogenic diabetes at 1, 3 and 6 months following surgery (P=0.634, 0.726 and 0.446, respectively). In the total diabetic group, the rebleeding rate in the Child‑Pugh grade A subgroup (14.3, 17.9 and 25.0%) was lower than that in the Child‑Pugh grade B/C subgroup (28.6, 45.2 and 59.5%) at 1, 3 and 6 months following surgery, respectively. No significant difference was noted between the two groups at 1 month following surgery (P=0.163). However, the differences were significant at 3 and 6 months following surgery (P=0.018 and 0.005, respectively). The results suggested that diabetes is a risk factor for post‑operative rebleeding in patients with cirrhosis. Diabetic patients with poor liver function were more likely to bleed following surgery and the post‑operative bleeding rate was not significantly different between patients with hepatogenic and non‑hepatogenic diabetes. The study was registered in the Chinese Clinical Trial Registry (no. ChiCTR1800017772).

Related Articles

Journal Cover

August-2020
Volume 20 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang X, Mei X and Kong D: Effects of diabetes on the rebleeding rate following endoscopic treatment in patients with liver cirrhosis. Exp Ther Med 20: 1299-1306, 2020
APA
Wang, X., Mei, X., & Kong, D. (2020). Effects of diabetes on the rebleeding rate following endoscopic treatment in patients with liver cirrhosis. Experimental and Therapeutic Medicine, 20, 1299-1306. https://doi.org/10.3892/etm.2020.8876
MLA
Wang, X., Mei, X., Kong, D."Effects of diabetes on the rebleeding rate following endoscopic treatment in patients with liver cirrhosis". Experimental and Therapeutic Medicine 20.2 (2020): 1299-1306.
Chicago
Wang, X., Mei, X., Kong, D."Effects of diabetes on the rebleeding rate following endoscopic treatment in patients with liver cirrhosis". Experimental and Therapeutic Medicine 20, no. 2 (2020): 1299-1306. https://doi.org/10.3892/etm.2020.8876